Live Analyst Rating Changes 8035 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Julian Harrison
BTIG
Julian Harrison
Wall Street Analyst
★★☆☆☆
#2066
on 13Foresight · ranked by our own returns
53%
Success Rate
+24.5%
Average Return
28 of 53 calls profitable · +17.3% vs benchmark
📈 Across the calls we could measure, roughly 53% of Julian Harrison's ratings turned a profit when each position was held for 2 year — averaging +24.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

168 Buy 9 Hold 0 Sell
Julian's Stock Coverage 38 ratings · 2026-07-13
Company Date Position Consensus Price Target 2-Yr Return
TVRD
Tvardi Therapeutics
Jul 07, 2026 BUY Strong Buy
+452.6% avg upside
23 analysts
$15.00
357.31% Upside
+57.7%
SYRE
Spyre Therapeutics
Jul 05, 2026 BUY Strong Buy
-20.9% avg upside
23 analysts
$112.00
14.58% Upside
+10.1%
LQDA
Liquidia Technologies
Jul 01, 2026 BUY Strong Buy
-27.4% avg upside
15 analysts
$109.00
39.86% Upside
-1.8%
RNAC
Cartesian Therapeutics
Jul 01, 2026 BUY Strong Buy
+234.2% avg upside
19 analysts
$44.00
365.11% Upside
·
ABVX
Abivax SA Sponsored ADR
Jun 30, 2026 BUY Strong Buy
-6.2% avg upside
15 analysts
$175.00
25.14% Upside
+5.0%
OTLK
Outlook Therapeutics
Jun 29, 2026 HOLD Buy
+462.7% avg upside
11 analysts
$1.61
2.47% Upside
-15.4%
TBPH
Theravance Biopharma
Jun 29, 2026 HOLD Buy
+8.9% avg upside
18 analysts
-0.3%
MLTX
MoonLake Immunotherapeutics
Jun 22, 2026 BUY Buy
+43.0% avg upside
20 analysts
$30.00
47.41% Upside
-8.1%
INVA
Innoviva
Jun 22, 2026 BUY Buy
+28.6% avg upside
12 analysts
$42.00
88.91% Upside
-1.1%
APGE
Apogee Therapeutics
Jun 19, 2026 BUY Buy
-7.3% avg upside
19 analysts
$137.00
2.41% Upside
+0.8%
CNTB
Connect Biopharma Holdings
Jun 17, 2026 BUY Strong Buy
+161.7% avg upside
12 analysts
$10.00
298.32% Upside
·
CLYM
Climb Bio
Jun 11, 2026 BUY Strong Buy
+29.1% avg upside
18 analysts
$20.00
42.84% Upside
·
CGEM
Cullinan Management
Jun 10, 2026 BUY Strong Buy
+87.1% avg upside
15 analysts
$38.00
109.65% Upside
+50.5%
RZLT
Rezolute
Jun 02, 2026 BUY Strong Buy
+124.0% avg upside
13 analysts
$6.00
26.40% Upside
+18.8%
JBIO
Jade Biosciences
Jun 01, 2026 BUY Strong Buy
+167.3% avg upside
16 analysts
$74.00
253.22% Upside
+12.7%
ORKA
Oruka Therapeutics
May 13, 2026 BUY Strong Buy
+37.4% avg upside
16 analysts
$151.00
73.98% Upside
+37.4%
AVTX
Avalo Therapeutics
May 13, 2026 BUY Strong Buy
+174.2% avg upside
20 analysts
$58.00
201.93% Upside
-17.6%
NKTR
Nektar Therapeutics
May 07, 2026 BUY Strong Buy
+1.0% avg upside
25 analysts
$178.00
152.91% Upside
-15.6%
AKBA
Akebia Therapeutics
Apr 06, 2026 BUY Strong Buy
+604.7% avg upside
16 analysts
$4.00
185.74% Upside
+7.6%
MAZE
Maze Therapeutics, Inc.
Mar 25, 2026 BUY Strong Buy
+106.1% avg upside
12 analysts
$46.00
50.52% Upside
-3.7%
MREO
Mereo Biopharma Group Plc
Mar 19, 2026 BUY Strong Buy
+1056.7% avg upside
11 analysts
$1.00
198.50% Upside
-33.3%
UTHR
United Therapeutics
Feb 25, 2026 HOLD Strong Buy
-22.7% avg upside
26 analysts
+1.4%
ARDX
Ardelyx
Feb 20, 2026 BUY Strong Buy
+156.7% avg upside
21 analysts
$17.00
221.93% Upside
-5.9%
VRDN
Viridian Therapeutics
Nov 04, 2025 BUY Strong Buy
+78.3% avg upside
32 analysts
$61.00
209.10% Upside
-12.5%
PTGX
Protagonist Therapeutics
Nov 03, 2025 BUY Strong Buy
-30.7% avg upside
19 analysts
$82.00
37.54% Downside
+81.2%
VYNE
VYNE Therapeutics
Jul 31, 2025 HOLD Strong Buy
+2017.3% avg upside
9 analysts
+74.3%
RANI
Rani Therapeutics Holdings
Mar 31, 2025 BUY Strong Buy
+1282.4% avg upside
10 analysts
$14.00
1937.29% Upside
-41.1%
ZLDPF
Zealand Pharma
Mar 17, 2025 BUY Buy
+89.5% avg upside
11 analysts
$160.33
257.47% Upside
·
KROS
Keros Therapeutics
Dec 12, 2024 HOLD Strong Buy
+115.7% avg upside
21 analysts
-43.0%
ANAB
AnaptysBio
Dec 02, 2024 HOLD Strong Buy
+9.2% avg upside
26 analysts
+308.5%
ACRS
Aclaris Therapeutics
Nov 18, 2024 BUY Strong Buy
+79.2% avg upside
15 analysts
$8.00
43.32% Upside
+77.1%
AURA
Aura Biosciences Inc
Nov 13, 2024 BUY Strong Buy
+209.1% avg upside
9 analysts
$24.00
250.79% Upside
-33.8%
MTNB
Matinas BioPharma
Nov 09, 2023 BUY Buy
+1733.7% avg upside
7 analysts
$50.00
6519.79% Upside
-89.4%
BIORQ
Biora Therapeutics
May 03, 2022 BUY Strong Buy
+269249900.0% avg upside
6 analysts
$4.00
3999899.97% Upside
·
VKTX
Viking Therapeutics
Apr 28, 2021 BUY Strong Buy
+85.1% avg upside
31 analysts
$12.00
69.02% Downside
+235.1%
ALDX
Aldeyra Therapeutics
Apr 27, 2021 BUY Strong Buy
+670.4% avg upside
21 analysts
$29.00
1301.04% Upside
-39.1%
PLRX
Pliant Therapeutics
Apr 20, 2021 BUY Buy
+1889.7% avg upside
21 analysts
$51.00
4453.48% Upside
+3.5%
WHWK
Whitehawk Therapeutics
Dec 09, 2020 BUY Strong Buy
+225.1% avg upside
13 analysts
$60.00
1411.26% Upside
-57.1%
🔒 33 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Julian Harrison — Frequently Asked Questions
How accurate are Julian Harrison's stock ratings?
Based on the calls 13Foresight could measure, about 49% of Julian's ratings were profitable over a one-year hold, with an average return of +11.6% per rating, or +5.6% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Julian ranked on 13Foresight?
Julian Harrison is currently ranked #2066 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Julian cover?
Julian most recently has ratings on TVRD, SYRE, LQDA, RNAC, ABVX, OTLK, TBPH, MLTX, INVA, APGE, CNTB, CLYM and 26 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.